Acquired Company

Catalyst Biosciences completed the business combination with GNI Group Ltd. and related entities, and the combined company began operating as Gyre Therapeutics, Inc. (Beijing Continent Pharmaceuticals became a majority-owned subsidiary of Gyre).

Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates. Its pipeline includes CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics, including novel combinations. The company is headquartered in Waltham, Massachusetts. Show more

300 Fifth Avenue, Waltham, MA, 02451, United States

https://crescentbiopharma.com

Biotechnology

Healthcare

Start AI Chat

Market Cap

349.2M

52 Wk Range

$8.72 - $29.00

Previous Close

$11.47

Open

$11.50

Volume

239,906

Day Range

$11.50 - $13.50

Enterprise Value

54.89M

Cash

133.3M

Avg Qtr Burn

-17.54M

Insider Ownership

5.23%

Institutional Own.

87.52%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
CR-001 Details Solid tumor/s	Phase 1/2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CR-003 (Topoisomerase Inhibitor ADC) Details Solid Tumors	IND Acceptance decision	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CR-002 (Topoisomerase Inhibitor ADC) Details Solid Tumors	IND Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
SQ Dalcinonacog alfa (DalcA) Details Hemophilia, Genetic disorder	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Marzeptacog alfa (MarzAA) Details Hemophilia, Blood disorder, Rare genetic disease	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.